NCT05888233View on ClinicalTrials.gov

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Heart Failure Preserved Ejection FractionResistant Hypertension
Interventions
DRUG

Allopurinol

Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then may be increased to 600mg/daily for an additional 4 weeks.

Trial Locations (1)

35233-1927

RECRUITING

Birmingham VA Medical Center, Birmingham, AL, Birmingham

All Listed Sponsors
lead

VA Office of Research and Development

FED